Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 2Myeloid 1

Conditions

Multiple Myeloma 81Neoplasms, Plasma Cell 27Neoplasms 13Brain Neoplasms 11Prostatic Neoplasms 10Central Nervous System Neoplasms 10Melanoma 9Leukemia 9Glioblastoma 8Gliosarcoma 7Glioma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Hepatocellular 6Recurrence 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Waldenstrom Macroglobulinemia 4Sarcoma 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Immunoglobulin Light-chain Amyloidosis 4Carcinoma, Renal Cell 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3

Interventions

Cyclophosphamide 23fludarabine phosphate 20Cyclosporine 19Busulfan 17Peripheral Blood Stem Cell Transplantation 14Mycophenolic Acid 14Antilymphocyte Serum 13Whole-Body Irradiation 12Radiotherapy 11Cord Blood Stem Cell Transplantation 10Methotrexate 9Filgrastim 9Methylprednisolone 8Cytarabine 6sargramostim 5Tacrolimus 5Melphalan 5Etoposide 5Cyclosporins 4merphos 3fludarabine 3Transplantation 3Thiotepa 3Granulocyte Colony-Stimulating Factor 3Decitabine 3bryostatin 1 2aldesleukin 2Topotecan 2Thioguanine 2Thalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Anemia, Refractory × Thalidomide × Clear all
NCT00030550 2013-01-31

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Roswell Park Cancer Institute

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00015990 2013-01-24

Thalidomide in Treating Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2 Completed
29 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡